News

Century Therapeutics, Inc.: Century Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Patient dosing initiated in Phase 1 CALiPSO-1 trial evaluating CNTY-101 in autoimmune disease; expanding to additional U.S. and European sites following CTA authorizations in Germany, France, and Ital ...
KE Holdings Inc. (BEKE) Q1 2025 Earnings Call Transcript
Q1 2025 Earnings Conference Call May 15, 2025 8:00 AM ETCompany ParticipantsSiting Li - IR DirectorStanley Peng - ...
Santé log13h
Century Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Patient dosing underway in CALiPSO-1 trial in the U.S.: In March 2025, the first patient was dosed in the Phase 1 CALiPSO-1 trial which is currently evaluating CNTY-101 as a potential treatment for ...